Molecular mechanisms of fatty liver disease: role of the protein DBC1
脂肪肝疾病的分子机制:蛋白质 DBC1 的作用
基本信息
- 批准号:7848937
- 负责人:
- 金额:$ 37.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAgeAmericanAnimal ModelBindingBiochemicalCaloric RestrictionCardiovascular systemCell modelCessation of lifeDataDeacetylaseDeveloping CountriesDevelopmentDietDiseaseDissociationEnzymesFatty LiverFatty acid glycerol estersFutureGenesHealthHepaticInvestigationKIAA1967 geneKnock-outKnockout MiceLaboratoriesLeadLightLiverLiver diseasesLongevityMalignant NeoplasmsMediatingMetabolicMetabolic syndromeMetabolismMolecularMolecular Biology TechniquesMusOrganismPathway interactionsPatientsPhysiologicalPlayProcessProteinsPublic HealthRegulationReportingResistanceRoleStarvationTestingTherapeuticWild Animalsadenylate kinasebasefatty acid oxidationin vitro Assayin vivoinhibitor/antagonistlipid biosynthesislipid metabolismmeetingsmembermortalitynon-alcoholic fatty livernoveloxidationpublic health relevancetrend
项目摘要
DESCRIPTION (provided by applicant): Recently the American Association for the Study of Liver Disease stated that "...Overall, patients with non-alcoholic fatty liver disease (NAFLD) have reduced long-term survival, with liver disease accounting for about 10% of overall mortality.... Clearly it appears that NAFLD will become a more prevalent problem in coming years..." This indicates that NAFLD will become a major public health issue in the near future. However, to date, therapeutic options for this disease are limited. In this regard, it is imperative to further understand the molecular mechanisms that modulate the development of liver steatosis. We observed that the protein Deleted in Breast Cancer 1 (DBC1) plays a crucial role in the development of experimental liver steatosis. In particular we found that mice knocked out for DBC1 are resistant to high fat diet-induced liver steatosis, while the systemic metabolic syndrome was not ameliorated. This suggests that DBC1 controls intrinsic hepatic mechanisms involved in the development of liver steatosis. To date very little is known about the physiological and biochemical roles of DBC1, however recent studies indicate that DBC1 binds and inhibits the enzyme SIRT1. SIRT1 is a NAD-dependent deacetylase that controls metabolism, ageing and longevity. In fact, it has been proposed that SIRT1 is a metabolic master switch. Pharmacological activation of SIRT1 protects against liver steatosis, at least in part, via stimulation of the AMP kinase (AMPK) that subsequently decreases lipogenesis and increases fatty acid oxidation. Although the metabolic actions of SIRT1 are the subject of intense investigation; much less is known about regulation of SIRT1. In fact, the mechanisms that modulate SIRT1 expression and activity remain elusive. In this regard, the characterization of DBC1 as an endogenous inhibitor of SIRT1, and the determination of the mechanisms that regulate the DBC1-SIRT1 interaction are of extreme importance. It is possible that modulation of DBC1-SIRT1 interaction plays a key role in the regulation of SIRT1 function during different metabolic conditions, including diet-induced steatosis. An increase in interaction between DBC1 and SIRT1 may also provide the molecular basis for the decrease in SIRT1 activity reported in animal models of diet-induced liver steatosis. Thus, our Central Hypothesis is that DBC1 plays a crucial role in the development of liver steatosis by direct binding and inhibiting SIRT1, with the subsequent modulation of downstream effects of SIRT1 on hepatic lipogenesis and 2-oxidation via AMPK. To test this hypothesis, the following specific aims will be addressed: Aim 1. Study the role of SIRT1 in DBC1-mediated regulation of liver steatosis. Aim 2. Characterize the role of DBC1 in the regulation of SIRT1 activity during different caloric loads and determine the molecular mechanisms that regulate the DBC1-SIRT1 interaction. Aim 3. Determine the biochemical mechanisms, downstream from SIRT1, by which DBC1 regulates the development of liver steatosis: role of AMPK. Collectively, these studies will lead to an in depth and extremely novel understanding of the physiological roles of DBC1 as a regulator of SIRT1, liver fat metabolism and hepatic steatosis. PUBLIC HEALTH RELEVANCE: Non alcoholic fatty liver disease (NAFLD) is a major health problem worldwide. As recently stated by members of the future trend meeting of the American Association for the Study of Liver Disease, "...Overall, patients with NAFLD have reduced long-term survival, with liver disease accounting for about 10% of overall mortality, surpassed only by malignancy and cardiovascular deaths. Clearly it appears that NAFLD will become a more prevalent problem in coming years..." ). These alarming data and predictions clearly show that it is imperative to further understand the molecular mechanisms that modulate the development of liver steatosis.
描述(由申请人提供):最近美国肝病研究协会表示,“.总的来说,非酒精性脂肪性肝病(NAFLD)患者的长期生存率降低,肝脏疾病约占总死亡率的10%。显然,NAFLD在未来几年将成为一个更普遍的问题。“这表明NAFLD将在不久的将来成为一个主要的公共卫生问题。然而,迄今为止,这种疾病的治疗选择是有限的。在这方面,有必要进一步了解调节肝脏脂肪变性发展的分子机制。我们观察到乳腺癌1(DBC 1)中的蛋白激酶在实验性肝脂肪变性的发展中起着至关重要的作用。特别是,我们发现敲除DBC 1的小鼠对高脂饮食诱导的肝脏脂肪变性具有抗性,而全身代谢综合征没有改善。这表明,DBC 1控制参与肝脏脂肪变性发展的内在肝脏机制。迄今为止,对DBC 1的生理和生化作用知之甚少,但最近的研究表明,DBC 1结合并抑制SIRT 1酶。SIRT 1是一种NAD依赖性脱乙酰酶,控制新陈代谢、衰老和寿命。事实上,已经提出SIRT 1是代谢主开关。SIRT 1的药理学激活至少部分地通过刺激AMP激酶(AMPK)来防止肝脏脂肪变性,AMP激酶随后减少脂肪生成并增加脂肪酸氧化。虽然SIRT 1的代谢作用是深入研究的主题,但对SIRT 1的调节知之甚少。事实上,调节SIRT 1表达和活性的机制仍然难以捉摸。在这方面,DBC 1作为SIRT 1的内源性抑制剂的表征,以及调节DBC 1-SIRT 1相互作用的机制的确定是极其重要的。这是可能的,调控DBC 1-SIRT 1相互作用在调节SIRT 1功能在不同的代谢条件,包括饮食诱导的脂肪变性的关键作用。DBC 1和SIRT 1之间相互作用的增加也可能为饮食诱导的肝脏脂肪变性动物模型中报告的SIRT 1活性降低提供分子基础。因此,我们的中心假设是,DBC 1通过直接结合和抑制SIRT 1在肝脂肪变性的发展中起着至关重要的作用,随后通过AMPK调节SIRT 1对肝脂肪生成和2-氧化的下游作用。为了检验这一假设,将讨论以下具体目标:目标1。研究SIRT 1在DBC 1介导的肝脏脂肪变性调节中的作用。目标二。表征在不同热量负荷期间DBC 1在SIRT 1活性调节中的作用,并确定调节DBC 1-SIRT 1相互作用的分子机制。目标3.确定SIRT 1下游的生化机制,DBC 1通过该机制调节肝脏脂肪变性的发展:AMPK的作用。总的来说,这些研究将导致对DBC 1作为SIRT 1,肝脏脂肪代谢和肝脏脂肪变性的调节剂的生理作用的深入和非常新颖的理解。非酒精性脂肪肝(NAFLD)是一种全球性的主要健康问题。正如美国肝病研究协会未来趋势会议的成员最近所说,“.总体而言,NAFLD患者的长期生存率降低,肝脏疾病约占总死亡率的10%,仅超过恶性肿瘤和心血管死亡。显然,NAFLD在未来几年将成为一个更普遍的问题。" ).这些令人震惊的数据和预测清楚地表明,必须进一步了解调节肝脏脂肪变性发展的分子机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eduardo N Chini其他文献
Erratum to: Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer
- DOI:
10.1186/2049-3002-2-24 - 发表时间:
2014-11-04 - 期刊:
- 影响因子:5.300
- 作者:
Debarshi Roy;Susmita Mondal;Chen Wang;Xiaoping He;Ashwani Khurana;Shailendra Giri;Robert Hoffmann;Deok-Beom Jung;Sung H Kim;Eduardo N Chini;Juliana Camacho Periera;Clifford D Folmes;Andrea Mariani;Sean C Dowdy;Jamie N Bakkum-Gamez;Shaun M Riska;Ann L Oberg;Edward D Karoly;Lauren N Bell;Jeremy Chien;Viji Shridhar - 通讯作者:
Viji Shridhar
SEX DIFFERENCES IN THE NADsup+/sup HYDROLASE CD38 IN VIRAL MYOCARDITIS
病毒性心肌炎中 NAD+水解酶 CD38 的性别差异
- DOI:
10.1016/j.cardfail.2024.10.293 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:8.200
- 作者:
Gabriel Weigel;Damian Di Florio;Eduardo N Chini;DeLisa Fairweather - 通讯作者:
DeLisa Fairweather
Eduardo N Chini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eduardo N Chini', 18)}}的其他基金
CD38 modulation of NAD metabolism driving scleroderma pathogenesis
CD38 调节 NAD 代谢驱动硬皮病发病机制
- 批准号:
10733929 - 财政年份:2023
- 资助金额:
$ 37.4万 - 项目类别:
Role of CD38 in NAD metabolism: from the basic biology of aging to translation
CD38 在 NAD 代谢中的作用:从衰老的基础生物学到转化
- 批准号:
10116241 - 财政年份:2018
- 资助金额:
$ 37.4万 - 项目类别:
Role of CD38 in NAD metabolism: from the basic biology of aging to translation
CD38 在 NAD 代谢中的作用:从衰老的基础生物学到转化
- 批准号:
10372023 - 财政年份:2018
- 资助金额:
$ 37.4万 - 项目类别:
Targeting NAD Catabolism in Pancreatic Cancer Cells: Role of Small Molecule SIRT
靶向胰腺癌细胞中的 NAD 分解代谢:小分子 SIRT 的作用
- 批准号:
8738912 - 财政年份:2014
- 资助金额:
$ 37.4万 - 项目类别:
Molecular mechanisms of fatty liver disease: role of the protein DBC1
脂肪肝疾病的分子机制:蛋白质 DBC1 的作用
- 批准号:
8500250 - 财政年份:2009
- 资助金额:
$ 37.4万 - 项目类别:
Molecular mechanisms of fatty liver disease: role of the protein DBC1
脂肪肝疾病的分子机制:蛋白质 DBC1 的作用
- 批准号:
8288739 - 财政年份:2009
- 资助金额:
$ 37.4万 - 项目类别:
Molecular mechanisms of fatty liver disease: role of the protein DBC1
脂肪肝疾病的分子机制:蛋白质 DBC1 的作用
- 批准号:
7696756 - 财政年份:2009
- 资助金额:
$ 37.4万 - 项目类别:
Molecular mechanisms of fatty liver disease: role of the protein DBC1
脂肪肝疾病的分子机制:蛋白质 DBC1 的作用
- 批准号:
8091479 - 财政年份:2009
- 资助金额:
$ 37.4万 - 项目类别:
The Sir2-p53-IGF link in mammalian life-span control
Sir2-p53-IGF 与哺乳动物寿命控制的联系
- 批准号:
8529413 - 财政年份:2006
- 资助金额:
$ 37.4万 - 项目类别:
The Sir2-p53-IGF link in mammalian life-span control
Sir2-p53-IGF 与哺乳动物寿命控制的联系
- 批准号:
8707914 - 财政年份:2006
- 资助金额:
$ 37.4万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 37.4万 - 项目类别:
Research Grant